HTA Quarterly | Fall 2021

By Xcenda

In this issue, our editors examine ICER's approach to Unsupported Price Increase (UPI) assessments, how health disparities play a pivotal role in health outcomes of marginalized patient populations, and how the evolution of cancer therapeutics offers opportunities to gain insights from key opinion leaders in oncology. 

HTA Quarterly | Fall 2021

Elucidating ICER's methodologies for Unsupported Price Increase assessments

In 2017, the Institute for Clinical and Economic Review (ICER) received funding from Arnold Ventures to develop annual Unsupported Price Increase (UPI) assessments to identify whether drugs with recent substantial price increases are supported by clinical evidence. To date, 2 UPI reports have been published to account for price increases that occurred in 2017–2018 and in 2019, respectively; the next report evaluating price increases in 2020 will be available in November 2021. Recent payer research conducted by Xcenda in 2020 found that payers are using ICER’s UPI reports with two-thirds of payers (66%) reporting them to be somewhat to extremely useful and 61% reporting them as somewhat to extremely influential on coverage decisions. Therefore, it is important for manufacturers to be familiar with the methodological approach of these assessments to prepare for future negotiations with payers. This article discusses ICER’s approach to the UPI assessment, considerations for manufacturers, and reactions from stakeholders.
Abstract figure pushing pill up with US dollar sign

HTA Quarterly | Fall 2021

Health disparities and health technology assessment: Current value assessment frameworks fall short

Approaches taken by health technology assessment bodies may not be inclusive of all patient populations. Health disparities play a pivotal role in health outcomes of marginalized patient populations. While many health technology assessment organizations understand the importance of addressing health disparities, they rarely incorporate health disparities into the value assessment process.
Hands holding coins

HTA Quarterly | Fall 2021

Gaining real-world oncology insights from engagement of key opinion leaders through virtual and live solutions

Traditional approaches for cancer treatment have included surgery, radiotherapy, and chemotherapy. In recent decades, however, an intensifying body of knowledge surrounding the role of genomics and the immune system in cancer has led to the development of therapies targeted to specific molecular alterations and/or other biologic characteristics (eg, immune suppression). This evolution in cancer therapeutics offers vast opportunities to learn from key opinion leaders in oncology. This article examines how provider and payer insights aid In overcoming oncology market access hurdles.
Insights written in the sky

HTA by the numbers

0.3%

Only 0.3% of COVID-19 vaccines worldwide have been administered in low-income countries; 83% of doses have been administered in high- and upper-middle-income countries.

NICE logo

Heard on the street

NICE logo

“The urgency of the pandemic led to necessary changes to the way NICE prioritised guidance production throughout 2020. As part of our 2021 review into the health technology evaluation process, we are taking this opportunity to introduce new measures to address the impact of the pandemic, including this pilot program for a limited fast-tracked process.”

Meindert Boysen, Director of the Centre for Health and Technology Evaluation at NICE. In August 2021, NICE recommended the first treatment, bimekizumab as a treatment option for severe plaque psoriasis, under a new pilot program that uses a subset of the appraisal committee to assess low-risk treatments


NICE logo